Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 756 entries
Sorted by: Best Match Show Resources per page
CD4-/CD56+/CD123+ Hematodermic Neoplasm Showing Early Liver Metastasis.

Annals of dermatology

Choi KW, Lee KY, Lee YK, Ku BS, Kim HS, Kim YH, Kim KH.
PMID: 20548910
Ann Dermatol. 2010 May;22(2):186-90. doi: 10.5021/ad.2010.22.2.186. Epub 2010 May 18.

Hematodermic neoplasm (HN) is a clinically aggressive neoplasm with a high incidence of cutaneous involvement and a risk of leukemic dissemination. In the recent WHO-EORTC classification, the term blastic natural killer cell lymphoma has been replaced with CD4+/CD56+ HN...

Cite
Choi KW, Lee KY, Lee YK, et al. CD4-/CD56+/CD123+ Hematodermic Neoplasm Showing Early Liver Metastasis. Ann Dermatol. 2010;22(2):186-90doi: 10.5021/ad.2010.22.2.186.
Choi, K. W., Lee, K. Y., Lee, Y. K., Ku, B. S., Kim, H. S., Kim, Y. H., & Kim, K. H. (2010). CD4-/CD56+/CD123+ Hematodermic Neoplasm Showing Early Liver Metastasis. Annals of dermatology, 22(2), 186-90. https://doi.org/10.5021/ad.2010.22.2.186
Choi, Kyu-Won, et al. "CD4-/CD56+/CD123+ Hematodermic Neoplasm Showing Early Liver Metastasis." Annals of dermatology vol. 22,2 (2010): 186-90. doi: https://doi.org/10.5021/ad.2010.22.2.186
Choi KW, Lee KY, Lee YK, Ku BS, Kim HS, Kim YH, Kim KH. CD4-/CD56+/CD123+ Hematodermic Neoplasm Showing Early Liver Metastasis. Ann Dermatol. 2010 May;22(2):186-90. doi: 10.5021/ad.2010.22.2.186. Epub 2010 May 18. PMID: 20548910; PMCID: PMC2883422.
Copy Download .nbib Format: NLM
Antileukemic activity of the leaf extract of Bischofia javanica blume on human leukemic cell lines.

Indian journal of pharmacology

Lingadurai S, Roy S, Joseph RV, Nath LK.
PMID: 21572647
Indian J Pharmacol. 2011 Apr;43(2):143-9. doi: 10.4103/0253-7613.77348.

OBJECTIVE: Leaves of Bichofia javanica (BJ) have been traditionally used for many ailments including cancer. In the present study, antileukemic activity of the leaf extract was evaluated on human leukemic cell lines.MATERIALS AND METHODS: Human leukemic cell lines U937,...

Cite
Lingadurai S, Roy S, Joseph RV, et al. Antileukemic activity of the leaf extract of Bischofia javanica blume on human leukemic cell lines. Indian J Pharmacol. 2011;43(2):143-9doi: 10.4103/0253-7613.77348.
Lingadurai, S., Roy, S., Joseph, R. V., & Nath, L. K. (2011). Antileukemic activity of the leaf extract of Bischofia javanica blume on human leukemic cell lines. Indian journal of pharmacology, 43(2), 143-9. https://doi.org/10.4103/0253-7613.77348
Lingadurai, Sutharson, et al. "Antileukemic activity of the leaf extract of Bischofia javanica blume on human leukemic cell lines." Indian journal of pharmacology vol. 43,2 (2011): 143-9. doi: https://doi.org/10.4103/0253-7613.77348
Lingadurai S, Roy S, Joseph RV, Nath LK. Antileukemic activity of the leaf extract of Bischofia javanica blume on human leukemic cell lines. Indian J Pharmacol. 2011 Apr;43(2):143-9. doi: 10.4103/0253-7613.77348. PMID: 21572647; PMCID: PMC3081451.
Copy Download .nbib Format: NLM
WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity.

Leukemia

Cilloni D, Carturan S, Maffè C, Messa F, Arruga F, Messa E, Pradotto M, Pautasso M, Zanone C, Fornaciari P, Defilippi I, Rotolo A, Greco E, Iacobucci I, Martinelli G, Lo-Coco F, Bracco E, Saglio G.
PMID: 20072158
Leukemia. 2010 Jan 14; doi: 10.1038/leu.2009.207. Epub 2010 Jan 14.

Core-binding factor (CBF) leukemias are characterized by a high degree of sensitivity to high-dose cytarabine (ARA-C) treatment and by a relatively favorable prognosis compared with most other forms of adult acute myeloid leukemia (AML). The molecular basis of the...

Cite
Cilloni D, Carturan S, Maffè C, et al. WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. Leukemia. 2010;doi: 10.1038/leu.2009.207.
Cilloni, D., Carturan, S., Maffè, C., Messa, F., Arruga, F., Messa, E., Pradotto, M., Pautasso, M., Zanone, C., Fornaciari, P., Defilippi, I., Rotolo, A., Greco, E., Iacobucci, I., Martinelli, G., Lo-Coco, F., Bracco, E., & Saglio, G. (2010). WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. Leukemia, . https://doi.org/10.1038/leu.2009.207
Cilloni, D, et al. "WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity." Leukemia vol. (2010). doi: https://doi.org/10.1038/leu.2009.207
Cilloni D, Carturan S, Maffè C, Messa F, Arruga F, Messa E, Pradotto M, Pautasso M, Zanone C, Fornaciari P, Defilippi I, Rotolo A, Greco E, Iacobucci I, Martinelli G, Lo-Coco F, Bracco E, Saglio G. WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. Leukemia. 2010 Jan 14; doi: 10.1038/leu.2009.207. Epub 2010 Jan 14. PMID: 20072158.
Copy Download .nbib Format: NLM
Granulocytic sarcoma: a systematic review.

American journal of blood research

Yilmaz AF, Saydam G, Sahin F, Baran Y.
PMID: 24396704
Am J Blood Res. 2013 Dec 18;3(4):265-70.

Granulocytic sarcoma also called myeloid sarcoma is an extramedullary tumor of immature granulocytic cells. It is a rare entity, and mostly accompanied by acute myeloid leukemia. It is observed during the course of myeloproliferative disorders especially in chronic myeloid...

Cite
Yilmaz AF, Saydam G, Sahin F, et al. Granulocytic sarcoma: a systematic review. Am J Blood Res. 2013;3(4):265-70
Yilmaz, A. F., Saydam, G., Sahin, F., & Baran, Y. (2013). Granulocytic sarcoma: a systematic review. American journal of blood research, 3(4), 265-70.
Yilmaz, Asu Fergun, et al. "Granulocytic sarcoma: a systematic review." American journal of blood research vol. 3,4 (2013): 265-70.
Yilmaz AF, Saydam G, Sahin F, Baran Y. Granulocytic sarcoma: a systematic review. Am J Blood Res. 2013 Dec 18;3(4):265-70. PMID: 24396704; PMCID: PMC3875275.
Copy Download .nbib Format: NLM
Vitamin D in combination cancer treatment.

Journal of Cancer

Ma Y, Trump DL, Johnson CS.
PMID: 20842231
J Cancer. 2010 Jul 15;1:101-7. doi: 10.7150/jca.1.101.

As a steroid hormone that regulates mineral homeostasis and bone metabolism, 1α, 25-dihydroxycholecalciferol (calcitriol) also has broad spectrum anti-tumor activities as supported by numerous epidemiological and experimental studies. Calcitriol potentiates the anti-tumor activities of multiple chemotherapeutics agents including DNA-damaging...

Cite
Ma Y, Trump DL, Johnson CS. Vitamin D in combination cancer treatment. J Cancer. 2010;1:101-7doi: 10.7150/jca.1.101.
Ma, Y., Trump, D. L., & Johnson, C. S. (2010). Vitamin D in combination cancer treatment. Journal of Cancer, 1101-7. https://doi.org/10.7150/jca.1.101
Ma, Yingyu, et al. "Vitamin D in combination cancer treatment." Journal of Cancer vol. 1 (2010): 101-7. doi: https://doi.org/10.7150/jca.1.101
Ma Y, Trump DL, Johnson CS. Vitamin D in combination cancer treatment. J Cancer. 2010 Jul 15;1:101-7. doi: 10.7150/jca.1.101. PMID: 20842231; PMCID: PMC2938072.
Copy Download .nbib Format: NLM
Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy.

Rare tumors

Goto H, Hagiwara S, Hirai R, Miyama T, Honda H, Tagashira A, Iizuka T, Mochizuki M, Teruya K, Kikuchi Y, Oka S, Miwa A.
PMID: 21464873
Rare Tumors. 2011 Mar 30;3(1):e11. doi: 10.4081/rt.2011.e11.

Plasmablastic lymphoma is a rare and aggressive malignancy strongly associated with HIV infection. The refractory/relapsed disease rate is high, and the survival rate is characteristically poor. There are no satisfactory salvage regimens for relapsed cases. We successfully performed autologous...

Cite
Goto H, Hagiwara S, Hirai R, et al. Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy. Rare Tumors. 2011;3(1):e11doi: 10.4081/rt.2011.e11.
Goto, H., Hagiwara, S., Hirai, R., Miyama, T., Honda, H., Tagashira, A., Iizuka, T., Mochizuki, M., Teruya, K., Kikuchi, Y., Oka, S., & Miwa, A. (2011). Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy. Rare tumors, 3(1), e11. https://doi.org/10.4081/rt.2011.e11
Goto, Hiroki, et al. "Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy." Rare tumors vol. 3,1 (2011): e11. doi: https://doi.org/10.4081/rt.2011.e11
Goto H, Hagiwara S, Hirai R, Miyama T, Honda H, Tagashira A, Iizuka T, Mochizuki M, Teruya K, Kikuchi Y, Oka S, Miwa A. Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy. Rare Tumors. 2011 Mar 30;3(1):e11. doi: 10.4081/rt.2011.e11. PMID: 21464873; PMCID: PMC3070448.
Copy Download .nbib Format: NLM
Intracranial primary dural diffuse large B-cell lymphoma successfully treated with chemotherapy.

International journal of clinical and experimental medicine

Brito AB, Reis F, de Souza CA, Vassallo J, Lima CS.
PMID: 24600506
Int J Clin Exp Med. 2014 Feb 15;7(2):456-60. eCollection 2014.

Diffuse large B-cell lymphoma (DLBCL) presented as a primary dural lesion is an extremely rare entity, which may be misdiagnosed as meningioma. Patients with symptomatic meningioma are usually treated with tumor resection. The five previously described cases of intracranial...

Cite
Brito AB, Reis F, de Souza CA, et al. Intracranial primary dural diffuse large B-cell lymphoma successfully treated with chemotherapy. Int J Clin Exp Med. 2014;7(2):456-60
Brito, A. B., Reis, F., de Souza, C. A., Vassallo, J., & Lima, C. S. (2014). Intracranial primary dural diffuse large B-cell lymphoma successfully treated with chemotherapy. International journal of clinical and experimental medicine, 7(2), 456-60.
Brito, Angelo Borsarelli Carvalho, et al. "Intracranial primary dural diffuse large B-cell lymphoma successfully treated with chemotherapy." International journal of clinical and experimental medicine vol. 7,2 (2014): 456-60.
Brito AB, Reis F, de Souza CA, Vassallo J, Lima CS. Intracranial primary dural diffuse large B-cell lymphoma successfully treated with chemotherapy. Int J Clin Exp Med. 2014 Feb 15;7(2):456-60. eCollection 2014. PMID: 24600506; PMCID: PMC3931605.
Copy Download .nbib Format: NLM
A case of the cauda equina syndrome associated with the intrathecal chemotherapy in a patient with primary central nervous system lymphoma.

Annals of rehabilitation medicine

Park S, Kang JI, Bang H, Kim BR, Lee J.
PMID: 23869341
Ann Rehabil Med. 2013 Jun;37(3):420-5. doi: 10.5535/arm.2013.37.3.420. Epub 2013 Jun 30.

The intrathecal chemotherapy with methotrexate and cytarabine arabinoside is used for the treatment and prophylaxis of the primary central nervous system lymphoma. The therapy may induce neurotoxicity including the cauda equina syndrome. We report a case of a 58-year-old...

Cite
Park S, Kang JI, Bang H, et al. A case of the cauda equina syndrome associated with the intrathecal chemotherapy in a patient with primary central nervous system lymphoma. Ann Rehabil Med. 2013;37(3):420-5doi: 10.5535/arm.2013.37.3.420.
Park, S., Kang, J. I., Bang, H., Kim, B. R., & Lee, J. (2013). A case of the cauda equina syndrome associated with the intrathecal chemotherapy in a patient with primary central nervous system lymphoma. Annals of rehabilitation medicine, 37(3), 420-5. https://doi.org/10.5535/arm.2013.37.3.420
Park, Seunglee, et al. "A case of the cauda equina syndrome associated with the intrathecal chemotherapy in a patient with primary central nervous system lymphoma." Annals of rehabilitation medicine vol. 37,3 (2013): 420-5. doi: https://doi.org/10.5535/arm.2013.37.3.420
Park S, Kang JI, Bang H, Kim BR, Lee J. A case of the cauda equina syndrome associated with the intrathecal chemotherapy in a patient with primary central nervous system lymphoma. Ann Rehabil Med. 2013 Jun;37(3):420-5. doi: 10.5535/arm.2013.37.3.420. Epub 2013 Jun 30. PMID: 23869341; PMCID: PMC3713300.
Copy Download .nbib Format: NLM
Rehabilitation for ataxia following chemotherapy for burkitt lymphoma involving the rectum.

Annals of rehabilitation medicine

Kim HS, Jung CO, Jeon HR, Sung LH.
PMID: 22977788
Ann Rehabil Med. 2012 Aug;36(4):578-83. doi: 10.5535/arm.2012.36.4.578. Epub 2012 Aug 27.

Burkitt lymphoma is a type of B-cell lymphoma that occurs mostly in children, and rarely in adults. The sporadic type is known to occur mostly at the ileum and cecum. Cytarabine, which is used for central nervous system prophylaxis...

Cite
Kim HS, Jung CO, Jeon HR, et al. Rehabilitation for ataxia following chemotherapy for burkitt lymphoma involving the rectum. Ann Rehabil Med. 2012;36(4):578-83doi: 10.5535/arm.2012.36.4.578.
Kim, H. S., Jung, C. O., Jeon, H. R., & Sung, L. H. (2012). Rehabilitation for ataxia following chemotherapy for burkitt lymphoma involving the rectum. Annals of rehabilitation medicine, 36(4), 578-83. https://doi.org/10.5535/arm.2012.36.4.578
Kim, Hyoung Seop, et al. "Rehabilitation for ataxia following chemotherapy for burkitt lymphoma involving the rectum." Annals of rehabilitation medicine vol. 36,4 (2012): 578-83. doi: https://doi.org/10.5535/arm.2012.36.4.578
Kim HS, Jung CO, Jeon HR, Sung LH. Rehabilitation for ataxia following chemotherapy for burkitt lymphoma involving the rectum. Ann Rehabil Med. 2012 Aug;36(4):578-83. doi: 10.5535/arm.2012.36.4.578. Epub 2012 Aug 27. PMID: 22977788; PMCID: PMC3438429.
Copy Download .nbib Format: NLM
Chromonychia secondary to chemotherapy.

Case reports in dermatology

Lopes M, Jordão C, Grynszpan R, Sodré C, Ramos-E-Silva M.
PMID: 23874292
Case Rep Dermatol. 2013 Jun 06;5(2):163-7. doi: 10.1159/000351874. Print 2013 May.

Chemotherapy drugs can affect the skin and its appendages. Several clinical presentations can be observed, depending on the affected structure. The most common dermatological side effect is chromonychia. The main causative agents are: (1) cyclophosphamide, which can provoke a...

Cite
Lopes M, Jordão C, Grynszpan R, et al. Chromonychia secondary to chemotherapy. Case Rep Dermatol. 2013;5(2):163-7doi: 10.1159/000351874.
Lopes, M., Jordão, C., Grynszpan, R., Sodré, C., & Ramos-E-Silva, M. (2013). Chromonychia secondary to chemotherapy. Case reports in dermatology, 5(2), 163-7. https://doi.org/10.1159/000351874
Lopes, Marien, et al. "Chromonychia secondary to chemotherapy." Case reports in dermatology vol. 5,2 (2013): 163-7. doi: https://doi.org/10.1159/000351874
Lopes M, Jordão C, Grynszpan R, Sodré C, Ramos-E-Silva M. Chromonychia secondary to chemotherapy. Case Rep Dermatol. 2013 Jun 06;5(2):163-7. doi: 10.1159/000351874. Print 2013 May. PMID: 23874292; PMCID: PMC3712806.
Copy Download .nbib Format: NLM
Chapter 2 cytarabine.

Profiles of drug substances, excipients, and related methodology

El-Subbagh HI, Al-Badr AA.
PMID: 22469172
Profiles Drug Subst Excip Relat Methodol. 2009;34:37-113. doi: 10.1016/S1871-5125(09)34002-9. Epub 2010 Mar 16.

No abstract available.

Cite
El-Subbagh HI, Al-Badr AA. Chapter 2 cytarabine. Profiles Drug Subst Excip Relat Methodol. 2010;34:37-113doi: 10.1016/S1871-5125(09)34002-9.
El-Subbagh, H. I., & Al-Badr, A. A. (2009). Chapter 2 cytarabine. Profiles of drug substances, excipients, and related methodology, 3437-113. https://doi.org/10.1016/S1871-5125(09)34002-9
El-Subbagh, Hussein I, and Al-Badr, Abdullah A. "Chapter 2 cytarabine." Profiles of drug substances, excipients, and related methodology vol. 34 (2009): 37-113. doi: https://doi.org/10.1016/S1871-5125(09)34002-9
El-Subbagh HI, Al-Badr AA. Chapter 2 cytarabine. Profiles Drug Subst Excip Relat Methodol. 2009;34:37-113. doi: 10.1016/S1871-5125(09)34002-9. Epub 2010 Mar 16. PMID: 22469172.
Copy Download .nbib Format: NLM
The Prognostic Impact of K-RAS Mutations in Adult Acute Myeloid Leukemia Patients Treated with High Dose Cytarabine.

Journal of the Egyptian National Cancer Institute

Ahmad EI, Gawish HH, Al-Azizi NM, El-Hefni AM.
PMID: 21415871
J Egypt Natl Canc Inst. 2009 Dec;21(4):343-50.

UNLABELLED: Activating point mutation of the RAS gene has been generally accepted as an oncogenic event in a variety of malignancies. It represents one of the most common genetic alterations in acute myeloid leukemia (AML). However there is still...

Cite
Ahmad EI, Gawish HH, Al-Azizi NM, et al. The Prognostic Impact of K-RAS Mutations in Adult Acute Myeloid Leukemia Patients Treated with High Dose Cytarabine. J Egypt Natl Canc Inst. 2009;21(4):343-50
Ahmad, E. I., Gawish, H. H., Al-Azizi, N. M., & El-Hefni, A. M. (2009). The Prognostic Impact of K-RAS Mutations in Adult Acute Myeloid Leukemia Patients Treated with High Dose Cytarabine. Journal of the Egyptian National Cancer Institute, 21(4), 343-50.
Ahmad, Ebtesam I, et al. "The Prognostic Impact of K-RAS Mutations in Adult Acute Myeloid Leukemia Patients Treated with High Dose Cytarabine." Journal of the Egyptian National Cancer Institute vol. 21,4 (2009): 343-50.
Ahmad EI, Gawish HH, Al-Azizi NM, El-Hefni AM. The Prognostic Impact of K-RAS Mutations in Adult Acute Myeloid Leukemia Patients Treated with High Dose Cytarabine. J Egypt Natl Canc Inst. 2009 Dec;21(4):343-50. PMID: 21415871.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 756 entries